Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Free Cash Flow (2019 - 2025)

Historic Free Cash Flow for Pliant Therapeutics (PLRX) over the last 7 years, with Q3 2025 value amounting to -$21.1 million.

  • Pliant Therapeutics' Free Cash Flow rose 3644.37% to -$21.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$158.8 million, marking a year-over-year decrease of 1621.01%. This contributed to the annual value of -$159.4 million for FY2024, which is 3587.0% down from last year.
  • As of Q3 2025, Pliant Therapeutics' Free Cash Flow stood at -$21.1 million, which was up 3644.37% from -$40.7 million recorded in Q2 2025.
  • In the past 5 years, Pliant Therapeutics' Free Cash Flow registered a high of -$13.9 million during Q1 2021, and its lowest value of -$49.1 million during Q1 2025.
  • Over the past 5 years, Pliant Therapeutics' median Free Cash Flow value was -$25.4 million (recorded in 2023), while the average stood at -$29.5 million.
  • As far as peak fluctuations go, Pliant Therapeutics' Free Cash Flow tumbled by 36772.64% in 2021, and later surged by 3644.37% in 2025.
  • Quarter analysis of 5 years shows Pliant Therapeutics' Free Cash Flow stood at -$20.5 million in 2021, then tumbled by 53.52% to -$31.4 million in 2022, then increased by 19.88% to -$25.2 million in 2023, then crashed by 90.24% to -$47.9 million in 2024, then soared by 55.96% to -$21.1 million in 2025.
  • Its Free Cash Flow stands at -$21.1 million for Q3 2025, versus -$40.7 million for Q2 2025 and -$49.1 million for Q1 2025.